Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief ...

Orchestra BioMed holds two best-in-class medical device therapies targeting large markets. Find out why OBIO stock is a Buy.

May 28 (Reuters) - Boston Scientific (BSX.N), opens new tab said on Wednesday it will stop pursuing U.S. approval for its experimental heart device due to increased clinical and regulatory ...